All articles tagged with #g9a enzyme
University of Barcelona researchers report that FLAV-27, a first-in-class SAM-competitive G9a inhibitor, reverses cognitive deficits in multiple Alzheimer’s disease mouse models by reprogramming neuronal gene activity, a mechanism distinct from beta-amyloid–targeting drugs; the compound is currently in preclinical stages and could represent a disease-modifying approach pending human safety data.
A breakthrough in breast cancer research has uncovered how to target "hibernating" tumour cells, offering new hope for patients with oestrogen receptor-positive breast cancer. Scientists discovered that hormone therapies can trigger changes in some cells, causing them to lie dormant instead of dying off and leading to a relapse years later. Inhibiting the enzyme G9a prevented cancer cells from becoming dormant and killed the cells that were already hibernating, potentially paving the way for innovative treatments to prevent breast cancer from recurring.